Aspen Group Founder Dr Stephen Saad Explains why South Africa Needs To Have Its Own Anaesthetics Manufacturing Line
Aspen Group Founder Dr Stephen Saad Explains why South Africa Needs To Have Its Own Anaesthetics Manufacturing Line. In an interview with SABC News, founder of Aspen Group Dr Stephen Saad explained why South Africa needs to have its own Anaesthetics Manufacturing line.
He said, “When people get ill, they need to go to hospital and they require Anaesthetics so it’s to have that capability on your own country tod do it yourself, at least in line with other countries, which is an opportunity we never had as a country. From that perspective I think as a continent we should be looking at life saving, critical medicines as a priority for local manufacturing.”
With big South African companies such as Aspen Group willing to invest in building manufacturing plants in the country, the development of industries will surely be accelerated and thus resulting in job opportunities for the people of South Africa. Making sure that products are no longer imported is important to show the company’s capability of manufacturing the products.
The company’s manufacturing capabilities cover a wide variety of product types including steriles, oral solid dose, liquids, semi-solids, biologicals and active pharmaceutical ingredients. It operates 23 manufacturing facilities across 15 sites and it holds international manufacturing approvals from some of the most stringent global regulatory agencies including, among others, the United States Food and Drug Administration, the Australian Therapeutic Goods Administration and the European Directorate for the Quality of Medicines.
With a 160-year heritage, Aspen is a global specialty and branded multinational pharmaceutical company with a presence in both emerging and developed markets. It has approximately 9 100 employees at 69 established offices in over 50 countries and it improves the health of patients in more than 150 countries through its high quality, affordable medicines. Aspen focuses on marketing and manufacturing a broad range of post-patent, branded medicines and domestic brands covering both hospital and consumer markets through its key business segments.
